Pfizer's Dolsten On Finding Ways To “Accelerate External Science”
Part 2 Of 2
Worldwide President of R&D Mikael Dolsten talked to Scrip about Pfizer's busy business development track record and the company's ambition to maintain its leadership in breast cancer.
You may also be interested in...
"I still remember how I screamed 'oh my god, it's just unbelievable,'" worldwide president R&D Mikael Dolsten told Scrip, reflecting on the moment he heard the first COVID-19 vaccine results.
Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.
With cash to spend and a patent cliff to overcome starting in 2025, Pfizer is expected to be a prolific deal-maker in 2022.